NATIONAL CANCER INSTITUTE COOPERATIVE HUMAN TISSUE NETWORK
RFA AVAILABLE: 90-CA-01
P.T. 34, FF, II; K.W. 0780000, 0780020, 0715035
National Cancer Institute
Letter of Intent Receipt Date: January 12, 1990
Application Receipt Date: April 25, 1990
The Diagnosis Research Program of the Division of Cancer Biology and Diagnosis
at the National Cancer Institute (NCI) invites applications for Cooperative
Agreements from institutions capable of and interested in participating in The
Cooperative Human Tissue Network. The purpose of this established network is
to collect and distribute human tumor tissue and normal tissue to stimulate
research. The Network was developed in response to a growing need by
researchers for improved access to human tumor tissue. Basic and
developmental studies in many areas of cancer research, including molecular
biology, immunology and genetics, have been encouraged by improved access to
tissue. Hundreds of investigators have taken advantage of the existence of
the Network and thousands of tissues have been distributed since the inception
of the Network in January 1987. The NCI plans expand the Network from three
institutions to four or five institutions.
The existing Network has already demonstrated the feasibility of the network
approach and the continuing need of researchers for access to human materials.
Systems have been developed that allow efficient communication among
laboratories regarding tissue requests and availability. The Network is not a
tissue bank, but rather responds to investigator requests to meet existing
tissue requirements on a current basis. Applicants may plan for limited
storage of rare tumors that would otherwise not be available. Special
consideration will be given to ensuring access to and nationwide distribution
of rare pediatric tumor specimens.
Awards will be made as cooperative agreements which create an assistance
relationship with substantial involvement of NCI staff during the performance
of the project, as outlined in this request for applications (RFA). This
mechanism is used when the NCI wishes to stimulate investigator interest and
proposes to advise or assist in an important and opportune area of research.
The NCI anticipates making four or five awards for project periods of five
years. Although this project is provided for in the financial plans of the
NCI, the award of cooperative agreements pursuant to the RFA is contingent on
the availability of funds appropriated in fiscal year 1991.
Inclusion of women and minorities are encouraged. If they are excluded,
reasons for this exclusion must be included in the application.
This RFA is a one-time solicitation with a specified deadline of April 25,
1990, for receipt of applications.
The RFA label available in the 10/88 revision of Application Form 398 must be
affixed to the bottom of the face page. Failure to use this label could
result in delayed processing of your application such that it may not reach
the review committee in time for review. In addition, the RFA number and
title should be typed on line 2 of the face page of the application form.
A copy of the complete RFA describing eligibility criteria, the research goals
and scope, the cooperative agreement mechanism, the review criteria and the
method of applying should be obtained before beginning the application
process. Copies of the complete RFA can be obtained from:
Roger L. Aamodt Ph.D.
Program Director for Pathology and Cytology
Diagnosis Program
Division of Cancer Biology and Diagnosis
National Cancer Institute
Executive Plaza South, Room 638
6120 Executive Boulevard
Rockville, Maryland 20892
Telephone: (301) 496-7147
Inquiries concerning this RFA are encouraged and should be directed to Dr.
Aamodt at the address or telephone number listed above.
This program is described in the catalog of Federal Domestic Assistance no
13.394, Cancer Detection and Diagnosis Research. Awards are under
authorization of the Public Health Service Act, Title IV, Part A (Public Law
78-410 as amended: 42 USC 241) and administered under PHS grant policies and
Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not
subject to the intergovernmental review requirements of Executive Order 12372
or Health Systems Agency review.
